Project Grant R43AG066380

The National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded Redwood Neuro Inc. a $506,061 project grant to develop the SIMOLISA platform, an innovative and affordable immunoassay technology designed to enhance the detection of critical Alzheimer's disease (AD) biomarkers such as p-tau proteins and b-amyloid. The SIMOLISA platform aims to democratize early detection and longitudinal monitoring of AD by delivering advanced biomarker analysis...

This Project Grant award for $498,366.00 from the National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), aims to develop a platform for single-cell capture, immunolabeling, and high-resolution imaging of peripheral blood mononuclear cells (PBMCs) in arrays of bottomless microscopic conical wells with picoliter volumes. The goal is to effectively implement the "Imaging-based Chromatin and Epigenetic Age (IMAGE) Analysis" approach, which captures changes in...

The U.S. National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded Adeptrix Corp a $499,940 Project Grant on September 11, 2025 to develop TAUTRACE, an ultrasensitive immunoassay platform capable of quantifying distinct molecular forms of the tau protein biomarker in cerebrospinal fluid and plasma down to femtogram/milliliter concentrations. This novel technology aims to enable more sensitive detection and measurement of tau proteoforms, which are...

This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop a new blood-based biomarker for the early detection and monitoring of Alzheimer's disease (AD). The $431,826 award, made on September 15, 2024, will fund the development of monoclonal antibodies to detect a newly discovered, neurotoxic amyloid-beta (Aβ) peptide dimer that is specific to AD pathology in the brain. The project involves the University of Wollongong conducting...

This Project Grant award of $426,555 from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop a novel molecular diagnostic technology called "Cascade Amplification by Recycling Trigger Probe" (CARTP) for rapid, multiplex, and ultra-sensitive detection of circulating microRNA biomarkers in clinical plasma samples for early Alzheimer's disease detection. The project will (1) develop the CARTP method for multiplex microRNA biomarker detection, and (2) evaluate...

This Project Grant award of $483,346 from the National Institute on Aging (CFDA 93.866 - Aging Research) is supporting the development of a reverse transcription quantitative PCR (RT-qPCR) assay for the early diagnosis of Alzheimer's disease (AD). The project aims to utilize changes in the T cell receptor (TCR) clonality of CD8+ T cells in peripheral blood as a potential biomarker for AD and mild cognitive impairment (MCI). Based on preliminary findings, the awardee, Meganano Diagnostics Inc.,...

The National Institute on Aging (NIA) awarded a $459,250 Project Grant (CFDA 93.866 - Aging Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to investigate and validate the use of dried blood spot (DBS) samples for measuring Alzheimer's disease (AD) biomarkers. The key objectives are to: 1) optimize fingerstick collection methods and validate assays for three key AD biomarkers (pTau217, GFAP, and NFL) in DBS samples; 2) establish if DBS...

This $527,129 Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) supports research to identify biomarkers and develop novel strategies to prevent or treat inflammation-associated comorbidities in people living with HIV on antiretroviral therapy. The award recipient, Northwestern University, will conduct research to examine how glycomic alterations in circulating IgGs may contribute to HIV-associated inflammation and identify these alterations as potential...

The General Hospital Corporation (MGH) Research Management Division was awarded a $458,585 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) to develop a method for detecting autoantibodies against beta-amyloid in serum as a potential biomarker for Alzheimer's disease (AD). The 2-year project aims to investigate the use of small molecule compounds called CRANAD-XS to differentially tune the binding between beta-amyloid and its...

This $320,511 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to TRU Diagnostics Inc. aims to develop a transformative diagnostic tool for chronic diseases. The key products to be delivered include: A non-stochastic "W function" epigenomic roadmap that systematically quantifies the dynamic interactions of epigenetic markers over time using longitudinal data, addressing limitations of current diagnostic methods that rely on stochastic and causal...